The role of renal chloride channel mutations in kidney stone disease and nephrocalcinosis.

Article Details

Citation

Thakker RV

The role of renal chloride channel mutations in kidney stone disease and nephrocalcinosis.

Curr Opin Nephrol Hypertens. 1998 Jul;7(4):385-8.

PubMed ID
9690036 [ View in PubMed
]
Abstract

Recent advances in molecular biology have characterised a new class of chloride channels (CLCs) that are referred to as voltage-gated CLCs. To date nine such voltage-gated CLCs (CLC-1 to CLC-7, CLC-Ka and CLC-Kb, which are encoded by the genes CLCN1 to CLCN7, CLC-Ka and CLC-Kb, respectively) have been identified in mammals. Mutations in two of these, CLC-5 and CLC-Kb, have been defined in the hypercalciuric nephrolithiasis disorders of Dent's disease and a form of Bartter's syndrome, respectively. In addition, other forms of Bartter's syndrome have been defined with mutations involving the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC2) and the potassium channel ROMK. Finally, mutations of the thiazide-sensitive sodium-chloride cotransporter (NCCT) are associated with Gitelman's syndrome, in which hypocalciuria and hypomagnesaemia are notable features. These molecular genetic studies have increased our understanding of the renal tubular mechanisms that regulate mineral homeostasis.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
BumetanideSolute carrier family 12 member 1ProteinHumans
Yes
Inhibitor
Details